HCP

Clasado Biosciences has poster accepted at ISAPP 2022

Clasado Biosciences will showcase its class-leading science at 2022 International Scientific Association for Probiotics and Prebiotics (ISAPP) Annual Meeting, where its scientific poster has been accepted for presentation.

The conference, taking place June 15-17 in Barcelona, Spain, brings together ISAPP members across the globe to discuss the latest advances and findings in prebiotic and probiotic microbiome science.

Representing a key part of the event, delegates are invited to submit scientific posters to be presented, which detail an important clinical study or finding. Clasado will be presenting a summary of research studies into the health-related effects of galactooligosaccharide (GOS) ingredient, Bimuno® GOS.

The poster presentation has been collated and developed by Clasado team members Dr Gediminas Baltulionis, Scientist and R&D Specialist, Dr Sophie Castle, Nutritionist and HCP Engagement Manager and Dr Lucien Harthoorn, R&D Director.

Dr Baltulionis comments: “With 20 years of scientific validation behind Bimuno GOS, there is plenty to talk about with regards to its relationship with health and wellbeing. In fact, it’s the most studied commercially available prebiotic of its kind, backed by over 100 scientific papers and more than 20 clinical trials. The ISAPP Annual Meeting is a fantastic opportunity to highlight several compelling examples that demonstrate the important role of prebiotics in the future of health and wellbeing.

“We are looking forward to putting the science behind Bimuno in the spotlight. Our presentation includes scientific evidence and clinical data around the ingredient’s three core areas of action – gastrointestinal health, immunity and cognitive health. An area we pride ourselves on is helping formulators transform leading-edge science into strong commercial propositions that lead to an increasing number of scientifically supported products in the market, which in turn, plays a role in supporting public health and improve consumer trust. ISAPP is a fantastic opportunity to showcase that intersection of scientific research and product development.”

Bimuno GOS is scientifically proven to be more selective towards bifidobacteria when compared to other recognized prebiotics, where levels were proven to be increased within 7 days following administration of Bimuno GOS.

A large number of studies have shown that this GOS can improve gastrointestinal health and associated quality of life, strengthen anti-pathogenic activity, improve immune function, and enhance cognitive health related to stress, mood and anxiety. Given GOS’ useful properties as a food ingredient, including its stability and versatility, there is growing interest in including Bimuno GOS as a functional ingredient.

The business has also recently announced that Bimuno GOS has received a positive opinion from the European Food Safety Authority (EFSA) regarding its use in Food for Special Medical Purposes (FSMP), accelerating the ingredient’s journey to approved use in medical food-based applications.

Dr Baltulionis added: “We look forward to meeting with our industry peers once again at ISAPP. Around the globe, the prebiotic category is growing at such a fast pace that it’s important to take the opportunity of stepping back to look at the bigger picture of how the industry is developing – particularly as the line between food and nutrition gets ever more blurred. We are thrilled at the opportunity to share our own perspective through the strong portfolio of studies behind Bimuno GOS.”

To find out more about Clasado Biosciences, please visit www.clasado.com